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Summary Pharmacokinetically guided dosing was performed in nine paediatric patients receiving etoposide. Doses on day 2 of a 2- or 3-day
schedule were adapted on the basis of the day-1 area under the plasma etoposide concentration vs time curve (AUC). The day-1 AUC was
estimated using a limited sampling model and the day-2 target AUC defined by the etoposide dose-AUC relationship observed in 33 children.
Target AUC values (4.6-8.2 mg ml-1 x min) were achieved with a high degree of precision and with little bias (mean error 11% and root mean
squared error 15% respectively). Pharmacokinetic parameters were similar to those reported previously in children, although interpatient
pharmacokinetic variability was less than that observed previously: plasma clearance, 23 (18-26) ml min-' m-2; volume of distribution at
steady state (Vdss), 6.0 (3.9-8.9) m-2; t,,2 254 (127-550) min (median and range). This study has demonstrated that pharmacokinetically
guided dosing with etoposide is feasible. However, pharmacokinetically guided dosing is likely to be of most benefit in patients with
abnormalities of renal or hepatic function, or in children with prior exposure to cisplatin.
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Etoposide is an active and widely used agent in paediatnic oncology.
Single-agent activity and efficacy when used in combination have
been shown for the majority of paediatric tumours and, in the UK,
most children with malignant disease will receive etoposide-
containing therapy at some point in their management. In adults, a
number ofstudies have shown acorrelation between etoposide phar-
macokinetics, i.e. area under the plasma concentration-time curve
(AUC), steady-state concentration or trough concentration, and
pharmacodynamic effects, most commonly acute haematological
toxicity (for example, Lokich and Corkery 1981; Aisner et al, 1982;
Bennett et al, 1987; Lokich et al, 1989; Fukuoka et al, 1991; Minami
et al, 1993; Kunitah and Watanabe, 1994; Boos et al, 1995). As there
is marked interpatient variability, but relatively little intra-patient
variation, in etoposide pharmacokinetics in both children (Lowis et
al, 1993) and adults (reviewed in Henwood and Brogden, 1990)
etoposide is a suitable drug for pharmacokinetically guided dosing.
Several accurate limited sampling models have been developed
for the estimation of etoposide exposure after either intravenous or
oral dosing (Joel et al, 1990; Miller and Tolley, 1994; Gentili et al,
1993), but to date the use ofthese models in targeted dosing studies
has not been explored. Furthermore, it remains to be shown whether
pharmacokinetically guided dosing is ofpractical clinical value.
We have previously reported a limited sampling model for the
estimation ofetoposide AUC in children after an intravenous dose,
which is based upon a single etoposide sample taken at the end ofa
1- to 4-h infusion (Lowis et al, 1993). The present report describes
nine patients in whom etoposide exposure was estimated using the
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above limited sampling model on the first day of therapy, and the
etoposide dose adjusted the next day in order to achieve a target
AUC. The aim of the study was to examine the feasibility and
accuracy ofadaptively controlling etoposide dosing in children.
MATERIALS AND METHODS
Study design
Patients were eligible if they were receiving conventional first- or
second-line therapy that included etoposide treatment over 3
consecutive days. The day-I etoposide dose was the dose required
by the patient's protocol (see below). For day 2, the dose was
calculated by multiplying the day-i dose (mg) by the ratio of the
AUC observed on day 1, as measured by the limited sampling
strategy, to the target AUC for that patient. The target AUC was
calculated from the patient's protocol dose and the previously
determined relationship between etoposide dose and AUC (Lowis
et al, 1993). To maintain the same overall dose in a given cycle, i.e.
that which would have been given in the absence of adaptive
dosing, a compensatory dose was given on day 3. Dose adjustment
was permissible only within an individual cycle oftreatment, with
no adjustment resulting in a daily dose of less than 50% or greater
than 150% ofthe protocol dose being allowed.
One exception to the above eligibility criteria was made in a
neuroblastoma patient who had failed to respond to conventional
therapy, and who received 2, not 3, days ofetoposide treatment. In
all patients, permission to make dose adjustments within one
course was obtained from the appropriate trial co-ordinators
before studies were performed. Ethical approval for the studies
described here was obtained from the Joint Ethics Committee of
Newcastle Health Authority and the University ofNewcastle upon
Tyne, and consent was obtained from parents and older children
before each study.
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Patients
Patients characteristics are summarized in Table 1. Nine patients
were investigated, six male and three female. Two patients had a
plasma clearance of [5'Cr]EDTA less than 60 ml min-' m-2, but
none had a plasma creatinine concentration above the age-related
upper limit of normal, and only one patient had previously
received cisplatin. No patient had abnormalities of liver function.
Four patients were receiving treatment for soft-tissue sarcoma
(planned dose 200 mg m-2daily for 3 days), and one each forEwing's
tumour(150 mg m-2 x 3 days), Wilms' tumour(200 mg m-' x3 days),
non-Hodgkin's lymphoma (200 mg m-2 day-' x 4) and primitive
neuroectodermal tumour (125 mg m-) day-' x 3). In the patient who
had failed to respond to conventional therapy for neuroblastoma the
planned dose was 200 mg m-2day-1 for 2 days. Chemotherapy admin-
istered as partofthe same course oftherapy was as follows: soft-tissue
sarcomas, ifosfamide; neuroblastoma and primitive neuro-ectodermal
tumour (PNET), vincristine and carboplatin; Ewing's tumour,
vincristine, cyclophosphamide and doxorubicin; Wilms' tumour,
ifosfamide; non-Hodgkin's lymphoma, cytarabine.
Investigations before study
Height and weight were recorded for each patient, and haemo-
globin, white cell, neutrophil, lymphocyte and platelet counts,
serum electrolyte, urea, creatinine, albumin, total bilirubin, alanine
transaminase and alkaline phosphatase levels were measured. The
glomerular filtration rate in each patient was measured as the
plasma clearance of [5'Cr]EDTA. When possible, renal function
was determined just before the cycle of chemotherapy to be
studied, and in all was within four cycles of chemotherapy from
the course studied.
Administration of etoposide and blood sampling
Etoposide was given intravenously at a concentration of
0.25 mg ml-' in 0.9% (w/v) saline as an infusion over 1-4 h
according to the relevant protocol. Etoposide was administered to
all patients through an indwelling double lumen central venous
catheter. Samples were taken from the opposite lumen, with
interruption of the infusion and removal of a 5- to 10-ml dead-
space volume before sampling. The dead-space volume was
returned to the patient after sampling. Etoposide was given before
other concomitant cytotoxic chemotherapy.
On day 1 oftherapy, 2-ml heparinized blood samples were taken
into lithium heparin before the infusion and at the end of infusion.
On day 2 oftreatment, samples were taken before, twice during, at
the end of infusion and after the infusion at 10, 20, 40 min, 1, 2, 4,
6, 8, 10 and 20 h (total 28 ml ofblood). Samples were centrifuged,
and plasma from samples collected on day I analysed immedi-
ately. Day-2 samples were stored at -20°C until analysis, which in
all cases was within 2 weeks.
The plasma etoposide concentration in the end of infusion day 1
sample was determined and the second dose ofetoposide, calculated
as described below, administered approximately 24 h after the first
dose. A third dose was administered in all but one patient, the third
dosebeing adjusted such thatthe totaletoposide dose administered on
the course studied was as defined by the relevant treatment protocol.
No blood sampling was performed during or after the third dose.
Etoposide concentrations in plasma and pharmacokinetic para-
meters were determined as described previously (Lowis et al,
1993). Linearity (r2 > 0.99) was demonstrated in each assay over
the range 0.2-20 ,ug ml-', with intra- and interassay coefficients of
variation for quality assurance (QA) samples (5 ,ug ml-') of 4%
and 8% respectively. To allow rapid dose calculation, determina-
tion of the end of infusion plasma etoposide concentration on day
1 was made using a limited standard curve (5, 10 and 20 ,ug ml-')
with at least four QA samples at 20 ,ug ml-'. Determination of
etoposide concentrations after full pharmacokinetic studies on day
2 was made using the full standard curve and 5 gg ml-' QA
samples. Pharmacokinetic parameters were calculated using
ADAPT II software, with maximum likelihood estimation.
Calculation of etoposide doses and estimation of the
bias and precision of adaptive dosing
In the present study, the dose administered to each patient on day 1
was based on body surface area, and was defined by the protocol
Table 1 Characteristics of patients studied
Patient Age Diagnosis SA Serum [51]Cr EDTA Concurrent drugs Previous Previous
no. (years, (m2) ifosfamide cisplatin
months) Urea Cr Alb SBR ALT t1 clearance 1 2 3
(mM) (gM) (g 1-1) (gM) (U l-1) (min) (ml min-' m-2)
1 18, 9 NBL 1.45 3.2 74 42 22 55 114 59 V Carbo +
2 11, 2 PNET 1.08 76 34 7 7 75 70 V Carbo
3 10, 6 STS 1.44 45 37 33 71 71 95 Ifos +
4 2, 2 STS 0.52 2.9 39 42 7 102 55 86 Ifos +
5 17, 6 STS 1.82 4.5 78 38 13 16 96 65 Ifos +
6 3, 7 STS 0.59 1.2 40 36 11 35 54 97 Ifos +
7 16, 3 Ewing's 1.64 61 39 8 16 63 77 V Cyclo Doxo
8 15,1 Wilms' 1.50 3.5 59 40 174 95 64 Ifos +
9 8, 4 NHL 0.97 80 58 Cyt
Mean 11 y6m 1.22 3.1 58 40 13 76 76 75
s.d. 6y 0.46 1.2 18 3 6 63 17 15
Median 11 y2 m 1.44 3.2 59 40 12 55 75 70
Abbreviations: SA, surface area; Cr, plasma creatinine; Alb, serum albumin; SBR, serum bilirubin; ALT, alanine transaminase; V, vincristine; Carbo, carboplatin;
Ifos, Ifosfamide; Cyclo, cyclophosphamide; Cyt, cytarabine; Doxo, doxorubicin; nBL, Neuroblastoma; PNET, primitive neuro-ectodermal tumour; STS, soft-tissue
sarcoma.
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Figure 1 The relationship between administered dose and the AUC of
etoposide in the first 33 paediatric patients. Each point is derived from a
single patient, and the line of regression is shown. Data are from Lowis et al
(1993)
for the disease being treated. The daily target AUC foreach patient
was defined by the equation:
AUC (mg ml x min) = (dose m-2 x 0.034) + 0.77(equation 1)
This equation was derived from the regression line relating etopo-
side AUC to administered dose in 33 paediatric patients (Lowis et
al, 1993, Figure 1).
The actual day-I AUC in each patient was estimated using
the previously validated limited sampling strategy (Lowis et
al, 1993):
1.17 x peak concentration x infusion time
(equation 2)
1 -e -(0.72 x K x infusion time)
where K = [5'Cr]EDTA elimination rate constant and peak concen-
tration is the measured day- I end of infusion etoposide concentra-
tion (Lowis et al, 1993).
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Figure 2 Relationship between dose administered on day 2 and etoposide
AUC in nine patients. Patient 1 is shown. The line is that given by linear
regression analysis
The dose in milligrams forday 2 was calculated according to the
equation:
Dose (mg) dose (mg) forday 1 AUC day 2
for day 2 AUC day 1 estimated
by equation 2
The dose administered on day 3 was calculated such that the total
dose after 3 days was identical to that specified by the protocol.
For each patient, the difference between the day-2 target and
measured AUC was calculated, and the mean error (ME) and root
mean squared error (RMSE) used as measurements of bias and
precision respectively (Sheiner and Beal, 1981). The measured
AUC on day 2 was calculated by fitting a compartmental model to
the etoposide concentration-time data, using software kindly
supplied by D'Argenio and Schumitzky (1979), as described
previously (Lowis et al, 1993).
Table 2 Pharmacokinetic parameters for each patient studied
Day 2 Model dependent
etoposide
Patient dose Vc Ke Kcp Kpc t1 t1 Clearance Vdss AUC
(I m-2) (min-') (min-') (min-') a I (ml min-' m-2) (I M-2) /100 mg m-2
(mg) (mg m-2) (min) (min) (mg ml-' min)
1 188 129 3.9 0.0045 0.0068 0.0084 39 323 17.6 7.1 5.7
2 133 123 3.6 0.0071 0.0097 0.0095 30 242 25.5 7.3 3.9
3 270 188 3.4 0.0070 0.0030 0.0047 58 250 24.0 5.6 4.2
4 100 192 2.0 0.0116 0.0385 0.0394 8 127 23.1 3.9 4.3
5 420 231 6.1 0.0038 0.0012 0.0027 115 406 23.2 8.9 4.3
6 152 241 3.7 0.0060 0.0007 0.0015 99 550 22.6 5.7 4.7
7 272 166 2.7 0.0091 0.0265 0.0225 13 185 24.9 6.0 4.0
8 210 140 3.7 0.0059 0.0039 0.0061 53 254 21.7 6.0 4.6
9 180 185 5.3 0.0043 0.0053 0.0100 41 273 22.9 8.1 4.4
Mean 177 3.8 0.0066 0.0106 0.0116 51 290 22.8 6.5 4.5
s.d. 42 1.2 0.0025 0.0130 0.0121 36 125 2.3 1.5 0.5
Median 185 3.7 0.0060 0.0053 0.0084 41 254 23.1 6.0 4.3
Range 123 2.0 0.0038 0.0007 0.0015 8 127 17.6 3.9 3.9
241 6.1 0.0116 0.0385 0.0394 115 550 25.5 8.9 5.7
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Figure 3 Relationship between target and measured etoposide AUC on
day 2 of treatment. The upper graph shows the relationship between the
target AUC and the measured AUC; the line of equality is shown, and the
lower graph is a residual plot
RESULTS
Pharmacokinetic parameters
Pharmacokinetic parameters for etoposide in the nine patients
studied here are summarized in Table 2. These parameters are
derived by simultaneously fitting a two-compartment open model
to the plasma etoposide concentrations measured on the first and
second days of treatment. Values for the terminal phase elimina-
tion half-life ranged between 127 and 550 min (CV 43%). Vdss
ranged from 3.9 to 8.9 1 m-2 (CV 23%), plasma clearance from 18
to 26 ml min-' m-2 (CV 10%) and AUC per lO0 mg m-2 from3.9 to
5.7 mg ml' x min (CV 12%). In contrast to data shown in Figure
1, a close correlation was seen between administered dose and
AUC of etoposide in these nine patients (Figure 2).
Adaptive control of etoposide dosing
There was a close correlation between target and measured AUC
on day 2 for the nine patients studied (r = 0.78, Figure 3). Both
absolute and percentage values ofthe ME and RMSE were used as
measurements of bias and precision, and are given in Table 3.
The estimated day-I AUC, target day-2 AUC and measured
day-2 AUC values are also shown in Table 3. The ME for
these data was 1.0 mg ml-' x min, or 11%, and the RMSE was
1.4 mg ml-' x min, or 15%. Figure 3 shows that there was a bias
towards overestimation of the dose required to achieve the target
AUC, which in three patients was between 16% and 28%. The
largest absolute and percentage error was seen in the patient (no.
6) with the largest measured AUC, and overall there was a trend
towards greater error in patients with higher measured AUC
values. It is possible that at high etoposide doses residual etopo-
side present from the first dose may cause the day-2 AUC to be
greater than expected.
DISCUSSION
The aims of this study were to document the feasibility and accu-
racy of adaptive control of etoposide therapy in children. Nine
patients were studied, and adaptive control of etoposide dosing
was successfully performed in every case. Using a single etopo-
side plasma concentration at the end of infusion, and the
[5'Cr]EDTA elimination rate constant, dosing with a ME of 11%
and RMSE of 15% for the target AUC on day 2 was achieved.
Adaptively controlled dosing with etoposide is therefore possible,
with little patient inconvenience and a high degree ofaccuracy.
The pharmacokinetic parameters for etoposide in the patients
studied here, although broadly similar to those reported previously
(Lowis et al, 1993), showed considerably less interpatient vari-
ability. Overall, the surface area-normalized plasma clearance
showed a CV of only 10%, and if patient 1 is excluded from the
analysis the CV falls to 5.3%. This is shown in Figure 2, which
illustrates the strong correlation between administered dose and
AUC in the present group of patients. Previously, CVs of 49%,
26%, 28% and 27% were found for the terminal phase-elimination
half-life, Vdss, plasma clearance and AUC per 100 mg m-2 respec-
tively (Lowis et al, 1993). Hence, the variation in etoposide clear-
ance, and therefore AUC, observed in the present study was
considerably less than in our previous group of patients.
Furthermore, the mean and median values for the plasma clearance
of etoposide are higher in the present group, and AUC values
correspondingly lower, than in the patients studied previously.
However, the two groups are not directly comparable; the patients
studied here were on average older (median age 11 years 2 months
vs 4 years 9 months for the 33 patients studied previously, Lowis
et al, 1993), and several of those previously studied were severely
unwell, whereas all of the patients in the present series were
asymptomatic.
It seems likely that lack of severe renal impairment and prior
exposure to cisplatin are the major reasons for the higher mean
plasma clearances of etoposide in the group of patients reported
here. Patient I was the only patient to have received cisplatin
before study, and this patient had a significantly lower etoposide
plasma clearance than the other patients in this group (z score =
-2.3). This patient had a [5LCr]EDTA clearance, which was at the
bottom of the normal range (59 ml min-' m-2) and the longest
[5'Cr]EDTA elimination half-life (114 min vs 77±23 min),
although no overt signs of renal impairment. It seems likely that
the reduced interpatient pharmacokinetic variability seen in this
group ofpatients was due to the fact that only one child had previ-
ously received cisplatin, as cisplatin therapy has previously been
shown to predict for reduced etoposide clearance (Pfluger et al,
1987, 1993; Relling et al, 1994).
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Table 3 Precision and bias of pharmacologically guided etoposide dosing
Day 1 Day 1 Day 1 Day2 Day2 Day 2 Day2
Patient etoposide infusion Peak EDTA estimated target AUC etoposide measured differences
dose time concn t12 AUC used dose AUC measured-target
(min) (pg ml-') (min) (mg ml-' min) (mg ml-' min) (mg ml-' min) AUC
(mg) (mg m-2) (mg) (mg m-2)
(mg mi-' min)(%
1 300 206 182 25.4 114 9.8 6.2 188 129 7.4 1.2 16
2 122 113 330 9.8 75 4.2 4.6 133 123 4.8 0.2 4
3 280 195 183 26.0 71 7.7 7.4 270 188 7.8 0.4 5
4 100 192 192 26.5 55 7.2 7.2 100 192 8.3 1.1 13
5 380 209 176 20.8 96 7.1 7.9 420 231 9.9 2.1 21
6 140 236 175 27.3 54 7.0 7.6 152 256 10.7 3.0 28
7 230 140 150 19.7 63 5.0 5.9 272 166 6.7 0.8 12
8 280 187 235 24.2 95 9.4 7.0 210 140 6.5 -0.6 -9
9 180 185 175 25.0 80 7.7 7.7 180 185 8.1 0.4 5
ME 1.0 11
RMSE 1.4 15
Previous studies involving targeted dosing with etoposide using
limited sampling methods have involved the administration of
etoposide as a continuous infusion over 3 or 5 days (Ratain et al,
1989, 1991; Joel et al, 1996). In addition, English et al (1996)
reported two anephric paediatric patients in whom targeted dosing
with both etoposide and carboplatin was possible using detailed
pharmacokinetic sampling over three doses. In this latter study,
etoposide exposure was within 14% ofthe target in all four courses
studied, despite etoposide plasma clearances varying between 14
and 23 ml min-' m-'.
Adaptive control of etoposide dosing based upon both pharma-
cokinetic and pharmacodynamic factors has been used by Ratain et
al (1989, 1991) to treat patients with small-cell lung cancer. In
these latter studies, dosing in the adaptive control arm was based
upon the pretreatment white cell count and the plasma etoposide
concentration at 24 h, and the pharmacodynamic target was a
chosen degree of haematological toxicity. Doses in the conven-
tional dosing arm were calculated according to body surface area.
Dose escalation using this approach was possible and patients in
the adaptive control arm received a dose that on average was 22%
greater than in patients treated without adaptive control.
More recently, Joel et al (1996) have reported the results of a
pharmacokinetically based dose escalation study of etoposide
given intravenously as a continuous infusion over 5 days. Dose
modifications after 18 and 66 h were performed on the basis of
plasma etoposide concentrations in order to achieve a target level
of 2, 3, 4 or 5 ,ug ml-'. Marked variability was seen in plasma
etoposide concentrations before adjustment (27-166% of the
target, with only 57% of patients within ± 20% of the target
concentration at the 2 tg ml-' level), and this was substantially
reduced after adjustment (54-137% oftarget, with 82% ofpatients
within ± 20% at 66 h. The total etoposide dose per cycle ranged
from 200 to 994 mg for the 2 ,ug ml-' cohort. In comparison, the
variability in AUC associated with dosing according to surface
area in the present study was between 97% and 129% (Table 3),
and in only one patient was an error in excess of 20% seen.
The value of any method for reducing interpatient pharmaco-
kinetic variability depends both on the therapeutic range for the
drug, and on the extent of variation present in the population. For
most chemotherapeutic drugs, a doubling in administered expo-
sure might be expected to have a significant effect on toxicity or
response, and a twofold range in exposure might be an acceptable
upper limit. By these criteria, surface area-based dosing would
appear to be satisfactory for the relatively homogeneous group of
patients studied here, and no benefit from adaptively controlled
dosing would be expected.
Furthermore, even if the accuracy of adaptive dosing based
upon a limited sampling model could be increased, this would be
most unlikely to result in clinically significant improvements, as
the pharmacokinetic variability seen after surface area-based
dosing is already low. In contrast, patients from our previous series
(Lowis et al, 1993), and in many other reported studies, have
shown much greater pharmacokinetic variability, and a benefit in
these patients might have been expected. It is therefore important
to define the population of patients receiving etoposide, identi-
fying those for whom conventional surface area-based dosing is
appropriate, and those for whom pharmacokinetically guided
dosing may offer some benefit. In the present series of children
relatively little interpatient variability was identified in pharmaco-
kinetic parameters. The reasons for this are not clear, although
only one patient had received prior cisplatin therapy. No benefit
from pharmacokinetically guided dosing was seen in these
patients, and further studies are indicated in order to identify those
patients for whom improved accuracy may be seen. The feasibility
of this study with minimal patient inconvenience has however
been demonstrated.
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